Page 9 - Synlogic Inc News Today

Dublin, Nov. 02, 2022 (GLOBE NEWSWIRE) -- The "Global Human Microbiome Market Size, Share & Industry Trends Analysis Report By Product, By Disease...

Dublin, Nov. 01, 2022 (GLOBE NEWSWIRE) -- The "Crohn's Disease Therapeutics Market Forecast - Epidemiology & Pipeline Analysis" report has been added...

MARKET OVERVIEW Crohn’s disease is an inflammatory bowel disease (IBD) that causes digestive tract inflammation, leading to abdominal pain, severe...

/PRNewswire/ -- The "Microbiome Global Market Report 2022, Type, Application, Technology" report has been added to ResearchAndMarkets.coms offering. The...

Dublin, Aug. 31, 2022 (GLOBE NEWSWIRE) -- The "Microbiome Global Market Report 2022, Type, Application, Technology" report has been added to...

– Three clinical data readouts across three programs expected in H2 2022 – – PKU Phase 3 readiness activities underway for planned start in H1 2023 – – ...

/PRNewswire/ -- The Microbiomes Market report offers information on several market vendors, including 4D pharma Plc, ENTEROME SA, Evelo Biosciences Inc.,...

The global microbiome therapeutics market is expected to exhibit an exponential CAGR of 62.9% during the forecast period 2018–2025.

Synlogic (NASDAQ:SYBX – Get Rating)‘s stock had its “buy” rating reissued by stock analysts at Chardan Capital in a report issued on Friday, TipRanks reports. They currently have a $9.00 price objective on the biotechnology company’s stock. SYBX has been the subject of several other research reports. Oppenheimer reduced their price target on shares of […]

Shares of Synlogic, Inc. (NASDAQ:SYBX – Get Rating) have been assigned a consensus recommendation of “Buy” from the six research firms that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year […]